What is P21?
P21 (P021) is a small synthetic peptide designed at the New York State Institute for Basic Research to mimic a fragment of ciliary neurotrophic factor (CNTF), a protein that supports nerve cell survival. In mice it improves learning and memory, increases hippocampal neurogenesis (new nerve cells in the brain's memory center), and in a triple transgenic Alzheimer model (mice bred to develop Alzheimer-like disease) reduces tau hyperphosphorylation, the protein change behind Alzheimer tangles, but no human trial or safety study has ever been published, so its evidence grade is animal-only. It has never been reviewed by FDA, is not on any 503A compounding list (FDA's lists of ingredients pharmacies may use), and is prohibited in sport under WADA section S0, the anti-doping ban on unapproved substances.
P21 is a synthetic adamantane-modified tetrapeptide derived from the active region of ciliary neurotrophic factor (CNTF). It is also known as P021, Ac-DGGLAG-NH2, CNTF peptide mimetic, Peptide 021, P21 peptide, P021 peptide.
How does it work?
P21 is proposed to act as a CNTF mimetic that inhibits leukemia inhibitory factor (LIF) signaling and increases brain-derived neurotrophic factor (BDNF) expression, which in turn promotes neurogenesis, neuronal maturation, and synaptic plasticity in the dentate gyrus. In the 3xTg-AD mouse it also reduced abnormal tau phosphorylation and soluble amyloid beta, an effect the authors attributed to increased BDNF activity. The adamantane modification was added to improve blood brain barrier penetration and oral stability. All of this comes from rodent and cell work.
| Cluster | Cognitive and neuroprotective |
|---|---|
| Routes | Oral in diet (mouse studies); Peripheral injection (mouse studies); Sold as oral capsules or injection by research chemical sellers (unapproved drugs when sold for human use) |
| Conditions studied | Cognitive decline and nootropic use |
| Record | v3, reviewed, verified Sep 29, 2026 |
What does the evidence say about P21?
Evidence consists of rodent studies from a single research group. Peripheral P21 improved short-term and spatial memory and increased dentate gyrus neurogenesis in normal adult mice (2010). Twelve months of oral P021 in 3xTg-AD mice starting at 9 to 10 months of age reduced tau pathology, lowered soluble amyloid beta, and rescued cognition, neurogenesis, and synaptic plasticity (2014). Later work reported effects in aged rats and mouse models of retinal degeneration and early development. No independent replication and no human data have been published.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 0 | n/a |
| Human observational studies | 0 | n/a |
| Animal studies | 3 | n/a |
| All indexed studies | 3 | n/a |
Human evidence
No human study of P21 has been published. No clinical trial registration, pharmacokinetic study, or safety report in humans was identified as of the last verification date.
Animal evidence
In normal C57BL/6 mice, peripheral P21 enhanced learning, short-term memory, and spatial reference memory and increased neurogenesis and maturation of newborn neurons in the dentate gyrus. In female 3xTg-AD mice fed P021 in the diet for 12 months, tau hyperphosphorylation at Alzheimer associated sites and soluble amyloid beta were reduced, and deficits in cognition, neurogenesis, and synaptic plasticity were rescued. Chronic treatment was described as well tolerated in mice, but formal toxicology has not been published.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice2010 PMID 20600002 | Mouse behavioral and histological study of peripherally administered P21Normal adult C57BL/6 mice | P21 enhanced learning, short-term and spatial reference memory, and increased neurogenesis and maturation of newborn neurons in the dentate gyrus | Evidence: Animal-only evidence |
| Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease2014 PMID 25046994 | 12 month oral (dietary) treatment study in a transgenic mouse modelFemale 3xTg-AD and wild type mice treated from 9 to 10 months of age | Reduced tau hyperphosphorylation and soluble amyloid beta, increased BDNF activity, and rescued cognition, neurogenesis, and synaptic plasticity | Evidence: Animal-only evidence |
| Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease2016 PMID 27400746 | Narrative reviewRodent models of Alzheimer's disease and aging | Summarizes the CNTF mimetic rationale for P021 and the rodent evidence; notes that human studies have not been performed | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Cognitive decline and nootropic use | Not graded | Semax, selank, dihexa, cerebrolysin, and related compounds are marketed for cognition. Cerebrolysin has small clinical trials in stroke and dementia, mostly outside the United States. Semax and selank have Russian clinical literature but no indexed US or EU randomized trials. Dihexa and P21 are animal-only. |
Is P21 legal in the United States?
FDA and compounding status
P21 is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list. It is therefore outside FDA's interim policy, and a 503A pharmacy has no federal basis to compound it from bulk. It is not eligible for 503B outsourcing.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
No regulatory events recorded.
Full tracker for P21 or the category-wide tracker.
Email me when P21's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of P21 used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Mouse studies delivered P021 orally in the diet or by peripheral injection at research doses that have no established human equivalent.
Routes reported
| # | Route |
|---|---|
| 1 | Oral in diet (mouse studies) |
| 2 | Peripheral injection (mouse studies) |
| 3 | Sold as oral capsules or injection by research chemical sellers (unapproved drugs when sold for human use) |
What are the side effects and interactions of P21?
Side effects
| # | Reported side effect |
|---|---|
| 1 | No human safety data of any kind |
| 2 | Rodent studies did not report toxicity, but no formal toxicology has been published |
| 3 | Theoretical concern that a growth factor mimetic could influence tumor growth (not studied) |
Interactions
| # | Interaction |
|---|---|
| 1 | No interaction data exist in any species |
Contraindications
| # | Contraindication |
|---|---|
| 1 | No human use is supported by evidence |
| 2 | Pregnancy and breastfeeding (no data) |
| 3 | Competitive athletes subject to WADA testing (prohibited at all times under S0) |
How do people access P21 legally?
Typical cost: Not available through licensed channels. Research chemical sellers list it, but those products are unapproved drugs when sold for human use and are not verified for identity or purity.
Access options
Not available
Not legally available for human use in the United States: no FDA approved product and no federal basis to compound it from bulk.
Not available
Not an FDA approved drug and not compoundable under 503A or 503B.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare P21
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names P21. [8] [9] [10]
Being offered does not change the legal status of P21. P21 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [4] [11]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [4] [5] [8] [12] [13] [14]
What that means for you
- A pharmacy that compounds P21 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [8] [12]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [5]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [15]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [16] [17]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [4]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, P21 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [6]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound P21, with or without a prescription. [11]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [18] [19] [20]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [10] [20] [21]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [5] [22] [23] [24] [25] [26]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [5]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [18]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [10]
- Pharmacy: Is this made for me on a prescription written in my name? [21]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [10] [20]
- Prescriber: What is the legal basis for a pharmacy to compound P21? Is it FDA approved or on the 503A bulks list? [5] [11]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [10]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [15]
Frequently asked questions
Is P21 legal in the United States?
P21 is not an approved drug anywhere, has never been reviewed by FDA for compounding (custom-making by a pharmacy), and is not a component of any approved product, so there is no FDA approved or lawfully compounded source of it for human use. It is sold online as a research chemical, and those products are not intended or permitted for people. Possession is not a criminal matter, but no clinic or pharmacy can lawfully dispense it. [4] [5]
Does P21 work for memory or Alzheimer's disease?
In mice, yes: P21 improved learning and memory in normal adult mice and, given orally for 12 months, reduced tau pathology and rescued cognition in a triple transgenic Alzheimer model. In humans, nobody knows. There has never been a human trial, a pharmacokinetic study, or a published safety report. PeptideAgent grades the evidence animal-only. [1] [2]
What are the side effects of P21?
There are no human safety data at all. Mouse studies did not report toxicity during chronic dosing, but no formal toxicology has been published. Because P21 mimics a neurotrophic growth factor, a theoretical effect on tumor growth has not been ruled out. [2] [3]
How is P21 taken?
In research it was given to mice in the diet or by peripheral injection. It is sold to people as capsules or injection vials with doses that are extrapolated from rodent work rather than measured in humans. No human dose has ever been established. [1] [2]
How much does P21 cost?
It is not available through licensed channels, so there is no pharmacy or telehealth price. Research chemical products exist but are unapproved drugs when sold for human use and are not tested for purity, so PeptideAgent does not report those prices as a cost of treatment. [4] [7]
Is P21 banned by WADA?
Yes. P21 has no approval from any government health authority for human use, which places it in section S0 (non-approved substances) of the WADA Prohibited List. It is prohibited at all times, in and out of competition. [6]
P21 vs Dihexa: which has better evidence?
Neither has any human data. Both are small synthetic cognitive peptides developed in academic labs, both improved memory in rodents, and both are sold only as research chemicals. P21 has a longer chronic dosing study in an Alzheimer mouse model (12 months); Dihexa was placed on and then withdrawn from the FDA Category 2 compounding list, while P21 has never been nominated at all. Both are animal-only. [2] [4]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Li B et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett 2010PubMed 20600002, 2010
- [2]Kazim SF et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2014PubMed 25046994, 2014
- [3]Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener 2016PubMed 27400746, 2016
- [4]FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list and withdrawn nominations, current as of April 22, 2026)FDA, 2026
- [5]FDA: Compounding and the FDA, questions and answersFDA, 2026
- [6]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [7]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [9]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020
- [10]FDA to telehealth companies: What to know when promoting compounded drugsFDA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 29). P21: evidence, legality, and access. https://peptideagent.ai/peptides/p21- HTML link
<a href="https://peptideagent.ai/peptides/p21">P21: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.